HOTCHKIS & WILEY's CNMD Position Overview
HOTCHKIS & WILEY (via Hotchkis & Wiley Capital Management LLC) currently holds 325,574 shares of CONMED Corporation (CNMD) worth $15.05 M, representing 0.04% of the portfolio. First purchased in 2026-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, HOTCHKIS & WILEY has maintained this position in CNMD for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 53,240 shares. Largest reduction occurred in Q3 2026, reducing 45,116 shares.
Analysis based on 13F filings available since 2013 Q2
HOTCHKIS & WILEY's CONMED Corporation (CNMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly CONMED Corporation (CNMD) Trades by HOTCHKIS & WILEY
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | -45,116 | Reduce 12.17% | 325,574 | $46.23 |
| Q2 2026 | +53,240 | Add 16.77% | 370,690 | $32.73 |
| Q1 2026 | +317,450 | New Buy | 317,450 | $35.36 |
HOTCHKIS & WILEY's CONMED Corporation Investment FAQs
HOTCHKIS & WILEY first purchased CONMED Corporation (CNMD) in Q1 2026, acquiring 317,450 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY has held CONMED Corporation (CNMD) for 3 quarters since Q1 2026.
HOTCHKIS & WILEY's largest addition to CONMED Corporation (CNMD) was in Q1 2026, adding 317,450 shares worth $11.23 M.
According to the latest 13F filing for Q3 2026, HOTCHKIS & WILEY's firm, Hotchkis & Wiley Capital Management LLC, owns 325,574 shares of CONMED Corporation (CNMD), valued at approximately $15.05 M.
As of the Q3 2026 filing, CONMED Corporation (CNMD) represents approximately 0.04% of HOTCHKIS & WILEY's publicly disclosed stock portfolio, making it one of their key holdings.
HOTCHKIS & WILEY's peak holding in CONMED Corporation (CNMD) was 370,690 shares, as reported at the end of Q2 2026.